Abstract:Previous reports have demonstrated a role for hedgehog signaling in melanoma progression, prompting us to explore the therapeutic benefit of targeting this pathway in melanoma. We profiled a panel of human melanoma cell lines and control melanocytes for altered expression of hedgehog pathway members and determined the consequences of both genetic and pharmacological inhibition of the hedgehog pathway activator Smoothened (SMO) in melanoma, both in vitro and in vivo. We also examined the relationship between altered expression of hedgehog pathway mediators and survival in a well-characterized cohort of metastatic melanoma patients with prospectively collected follow up information. Studies revealed that over 40% of the melanoma cell lines examined harbored significantly elevated levels of the hedgehog pathway mediators SMO, GLI2, and PTCH1 compared to melanocytes (p < 0.05). SMO inhibition using siRNA and the small molecule inhibitor, NVP-LDE-225, suppressed melanoma growth in vitro, particularly in those cell lines with moderate SMO and GLI2 expression. NVP-LDE-225 also induced apoptosis in vitro and inhibited melanoma growth in a xenograft model. Gene expression data also revealed evidence of compensatory up-regulation of two other developmental pathways, Notch and WNT, in response to hedgehog pathway inhibition. Pharmacological and genetic SMO inhibition also downregulated genes involved in human embryonic stem cell pluripotency. Finally, increased SMO expression and decreased expression of the hedgehog pathway repressor GLI3 correlated with shorter post recurrence survival in metastatic melanoma patients. Our data demonstrate that hedgehog pathway inhibition might be a promising targeted therapy in appropriately selected metastatic melanoma patients.

Disrupting Hedgehog signaling in melanocytes by SUFU knockout leads to ocular melanocytosis and anterior segment malformation

Dual Regulatory Functions of SUFU and Targetome of GLI2 in SHH Subgroup Medulloblastoma.

Differential regulation of Gli proteins by Sufu in the lung affects PDGF signaling and myofibroblast development.

MEKK2 and MEKK3 Suppress Hedgehog Pathway-Dependent Medulloblastoma by Inhibiting GLI1 Function

Suppressor of Fused Inhibits Skin Wound Healing

Suppressor of Fused inhibits mammalian Hedgehog signaling in the absence of cilia.

Members of the Rusc Protein Family Interact with Sufu and Inhibit Vertebrate Hedgehog Signaling.

Effects of Inhibition of Hedgehog Signaling on Cell Growth and Migration of Uveal Melanoma Cells.

Structural Insight into the Mutual Recognition and Regulation Between Suppressor of Fused and Gli/Ci.

Increasing Sufu gene dosage reveals its unorthodox role in promoting polydactyly and medulloblastoma tumorigenesis

Aberrant expression of sonic hedgehog pathway in colon cancer and melanosis coli

Hedgehog signaling is controlled by Rac1 activity

Kif7 regulates Gli2 through Sufu-dependent and -independent functions during skin development and tumorigenesis

TMEM216 promotes primary ciliogenesis and Hedgehog signaling through the SUFU-GLI2/GLI3 axis

Hedgehog Pathway Blockade Inhibits Melanoma Cell Growth in Vitro and in Vivo

P4HA2 hydroxylates SUFU to regulate the paracrine Hedgehog signaling and promote B-cell lymphoma progression

Hedgehog signaling downregulates Suppressor of Fused through the HIB/SPOP-Crn axis in Drosophila

Positive feedback of SuFu negating protein 1 on Hedgehog signaling promotes colorectal tumor growth

Interaction between the TP63 and SHH pathways is an important determinant of epidermal homeostasis

SCF (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma development

SASH1 impairs melanin synthesis and metastasis by down-regulating the TGF-β signaling pathway